bio-europe® 2017: nouscom ceo outlines cancer vaccine strategy
Published 6 years ago • 435 plays • Length 5:01Download video MP4
Download video MP3
Similar videos
-
7:00
bio-europe spring® 2017: biomunex ceo on earlier deals for cancer drugs
-
11:11
bio-europe spring® 2016: oryx ceo on research partnerships and cancer vaccine studies
-
6:13
bio-europe spring® 2017: biomunex cso defines lead compounds, early r&d plans
-
10:31
bio-europe spring 2019: virion ceo outlines plans for first broad-spectrum respiratory antiviral
-
8:49
bio-europe® 2018: biontech cbo outlines infectious disease ambitions
-
9:39
bio-europe spring® 2017: genentech's bd head spotlights neuroscience pipeline
-
1:30:41
bio-europe® 2017: successful corporate communications in a changing media and investment world
-
5:21
innovent biologics - concentrating on cancer cells
-
10:17
eu vaccine row: how did we get here? - bbc newsnight
-
2:31
cancer vaccine research - mayo clinic
-
1:00
cancer vaccine and immunotherapy: dr jyoti bala
-
1:29
connect, learn, and inspire: experience the esmo sarcoma and rare cancers congress 2025
-
10:27
bio-europe® 2016: biontech's sean marett explains genentech deal rationale
-
9:41
bio-europe® 2015: interview with sean marett, biontech
-
15:08
bio-europe spring® 2018: commercializing cell and gene therapies
-
6:53
eu regulator declares astrazeneca vaccine “safe and effective” - bbc news
-
2:43
how vaccines are approved in europe | european vaccination information portal
-
5:03
cancer vaccine trials—using same mrna tech behind covid shots—could launch in u.k. this september